semaglutide cardiac protection From diabetes drugs... to weight loss drugs... to cardiometabolic drugs? The SELECT trial may mark the beginning of that transition. Where do you think GLP-1 receptor agonists will stand 10 years from Ozempic and Mounjaro: Saving Your

doi: 10.3389/fimmu.2025.1620185 144 KimHJIngberDE

A study published in The strongest finding in the study was that the well-established link between impulsivity and violent behavior was substantially weaker among current GLP-1 users compared to former users, Daniel Semenza, the lead author of the study, as well as the director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, and an associate professor with the Rutgers School of Public Health, said in a press release

For the most comprehensive all-around program, Ivim Health (4.9) edges ahead with published clinical research and a cleaner compliance record

They cannot, on their own, establish that GLP-1 drugs are anti-aging medications for the general population